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Carbapenem-resistant isolates of Acinetobacter baumannii from intensive care units at Split University
Hospital, Split, Croatia, were studied. Most (100 of 106) had ISAba1 inserted upstream of a blaOXA-107 gene,
encoding an unusual OXA-51-type oxacillinase. Pulsed-field gel electrophoresis revealed that the isolates
formed three clusters belonging to the sequence group 2 (European clone 1) lineage.
An increasing trend toward multidrug resistance, including
carbapenem resistance, in Acinetobacter baumannii has been
observed in the past two decades. Carbapenem resistance
mechanisms in A. baumannii include the production of metallo-
-lactamases (MBLs) and carbapenem-hydrolyzing oxacilli-
nases, efflux mechanisms, and the loss of outer membrane
proteins, often in combination (6). These resistance mecha-
nisms pose a serious therapeutic threat, since carbapenems are
frequently used to treat otherwise resistant A. baumannii in-
fections.
Since 2002, increasing numbers of carbapenem-resistant iso-
lates of A. baumannii have been recovered at Split University
Hospital in Split, Croatia. Meropenem is prescribed at this
hospital more frequently than imipenem, while ertapenem has
only recently been licensed in Croatia. There are few published
data concerning carbapenem resistance in multidrug-resistant
isolates of A. baumannii from Croatia. The present study in-
vestigated the epidemiology and carbapenem resistance mech-
anisms of multidrug-resistant A. baumannii isolates endemic in
this regional teaching hospital.
Between 2002 and 2007, 106 nonrepetitive isolates of A.
baumannii with an unusual resistance profile were isolated
consecutively from two adult surgical intensive care units
(ICUs), a pediatric ICU, a neurosurgery ICU, and a general
surgery ICU at different locations in Split University Hospital
(a 1,651-bed university teaching hospital with facilities at three
sites). The hospital serves a pediatric and adult population of
ca.500,000 and is also a referral hospital for much of southern
Croatia (with a total population of ca. 1 million inhabitants).
Isolates were initially recovered on blood agar plates from
routine blood cultures, urine samples, wound exudates, cathe-
ter tip specimens, and bronchial secretions. Conventional bio-
chemical tests and the API 20NE system (bioMe´rieux, Marcy-
l’Etoile, France) were used to presumptively identify the
isolates as members of the Acinetobacter calcoaceticus-A. bau-
mannii complex. Isolates were confirmed to be A. baumannii
by the identification of an OXA-51-type enzyme (10) (see
below) and, for selected isolates, by tRNA spacer fingerprint-
ing (2).
Routine susceptibility testing used a disk diffusion method,
while MICs were determined by broth microdilution with
Mueller-Hinton broth in 96-well microtiter plates (1). Resis-
tance to imipenem and/or meropenem was confirmed using
Etests (AB Biodisk, Solna, Sweden). The isolates were also
tested for possible MBL production by using MBL Etests.
Multidrug resistance was defined as resistance to three or more
antimicrobial classes.
Crude bacterial DNA templates from bacterial cells were
prepared by boiling. Specific primers to detect the presence of
blaOXA23-like, blaOXA-24-like, blaOXA-51-like, and blaOXA-58-
like genes (10) and ISAba1 (9) were used in PCR mixtures
(50-l final volumes) containing 25 l of PCR master mix
(Roche Diagnostics, Burgess Hill, United Kingdom), 20 l of
ultrapure water, 1 l of each primer (50 M), and 2 l of the
DNA template. Cycling conditions comprised 95°C for 5 min,
followed by 30 cycles of 95°C for 1 min, 50°C for 1 min, and
72°C for 2 min, with final elongation at 72°C for 10 min, except
that an annealing temperature of 58°C was used to investigate
the possible location of ISAba1 upstream of blaOXA-51-like
genes. Amplicons from selected isolates were purified using
the QIAquick PCR purification kit (Qiagen, Hilden, Germany)
and sequenced using an ABI Prism 377 genetic analyzer (Ap-
plied Biosystems, Warrington, United Kingdom). A. bauman-
nii sequence groups were determined as described by Turton et
al. (8). Pulsed-field gel electrophoresis was performed follow-
ing macrorestriction with ApaI (5), with subsequent cluster
analysis as described previously (5).
All 106 isolates were multidrug resistant (Table 1), but sul-
bactam and colistin nonsusceptibility was not detected. The
imipenem MICs for the isolates were 2 to 32 g/ml, and the
meropenem MICs were 8 to 128 g/ml. Cumulative percent-
ages of A. baumannii isolates inhibited by imipenem and mero-
penem are shown in Table 2. All 106 isolates were negative for
MBL production according to the results of MBL Etests, but
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PCR revealed that each isolate possessed a blaOXA-51-like
gene. No other class D oxacillinase genes were detected by
PCR. All isolates with high-level carbapenem resistance (those
for which the imipenem or meropenem MIC was 8 g/ml
[94% of isolates]) had ISAba1 inserted upstream of the
blaOXA-51-like gene. Pulsed-field gel electrophoresis genotyp-
ing revealed that the 106 isolates formed three related clusters
(with 85% similarity) belonging to the sequence group 2
(European clone 1) lineage (i.e., that including the European
clone 1 reference strain RUH 2037). Sequencing of the
blaOXA-51-like genes (both strands) from six representative iso-
lates for which meropenem MICs were elevated revealed the
presence of the unusual OXA-107 enzyme.
The carbapenem-hydrolyzing class D -lactamases of A.
baumannii form four phylogenetic subgroups: OXA-23-like,
OXA-24 like, OXA-51-like, and OXA-58-like enzymes (6).
Since the discovery of OXA-51 in 2004, at least 39 related
enzymes in this group have been described (3). The first de-
scription of carbapenem-resistant clinical isolates of A. bau-
mannii in Croatia reported the presence of an OXA-69-like
oxacillinase (4). The unusual OXA-107 enzyme was first de-
tected in A. baumannii isolates from Poland and Slovenia (3)
and is closely related to OXA-69, with an amino acid change at
position 167 that replaces leucine with valine (3). OXA-107 is
not distinguished from OXA-69 by the multiplex PCR method
of Turton et al. (8). In the present study of isolates with
blaOXA-107 as the sole detectable carbapenemase gene, imi-
penem and/or meropenem resistance was associated with
ISAba1 in 94% of cases, supporting the suggestion of Turton et
al. (9) that the presence of ISAba1 upstream of a blaOXA-51-
like gene is associated with high-level meropenem resistance.
Sequence group 2 (European clone 1) is one of two major
lineages of multidrug-resistant A. baumannii that are wide-
spread in Europe (7), including Bulgaria, Germany, Greece,
The Netherlands, Norway, Poland, and Slovenia (7), but OXA-
107 appears to be an uncommon enzyme and may represent a
more recent evolutionary adaptation to antibiotic challenge
with carbapenems.
To our knowledge, this is the first extensive characterization
of clinical A. baumannii isolates producing a class D carbap-
enemase in Croatia. Colistin and sulbactam are often the only
remaining therapeutic options for the patients involved. The
fact that clonally related isolates were obtained over a number
of years suggests that these strains persisted unnoticed in the
hospital’s ICUs, which then served as reservoirs for patient
colonization, followed by patient-to-patient transmission or
common-source acquisition (e.g., through contaminated me-
chanical ventilation equipment). Enhanced infection control
measures should be employed to limit the spread of A. bau-
mannii strains within the hospital, and the consumption of
meropenem should be restricted in order to reduce the selec-
tion pressure in the hospital environment. Further studies in
other hospitals in Croatia are needed to evaluate possible
interhospital spread of multidrug-resistant A. baumannii
strains.
Nucleotide sequence accession number. The blaOXA-51-like
gene sequence determined in this study has been deposited in
GenBank under accession number EF650033.
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TABLE 1. MICs for 106 A. baumannii isolates from Split
University Hospital
Antibiotic
MIC (g/ml)
Range 50% 90%
Imipenem 2–32 4 8
Meropenem 8–128 8 32
Ceftazidime 128–128 128 128
Ceftriaxone 64–128 128 128
Cefepime 32–128 64 128
Ciprofloxacin 4–64 16 32
Amikacin 32–128 64 128
Gentamicin 8–128 128 128
Piperacillin-tazobactam 64–128 128 128
Ampicillin-sulbactam 1–4 1 2
Colistin 0.19–0.50 0.19 0.38
TABLE 2. Cumulative percentages of 106 A. baumannii isolates
from Split University Hospital that were inhibited
by imipenem and meropenem
Carbapenem
% Inhibited at antibiotic concn (g/ml) of:
0.5 1 2 4 8 16 32 64 128
Imipenem 31 71 85 93 100
Meropenem 64 80 87 98 100
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